4598 logo

Delta-Fly Pharma, Inc. Stock Price

TSE:4598 Community·JP¥5.8b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

4598 Share Price Performance

JP¥601.00
25.00 (4.34%)
JP¥601.00
25.00 (4.34%)
Price JP¥601.00

4598 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Moderate risk with adequate balance sheet.

5 Risks
0 Rewards

Delta-Fly Pharma, Inc. Key Details

JP¥0

Revenue

JP¥0

Cost of Revenue

JP¥0

Gross Profit

JP¥1.6b

Other Expenses

-JP¥1.6b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-169.07
0%
0%
0%
View Full Analysis

About 4598

Founded
2010
Employees
13
CEO
Kiyoshi Eshima
WebsiteView website
www.delta-flypharma.co.jp

Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.

Recent 4598 News & Updates

Recent updates

No updates